Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
April 22, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
April 02, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
April 01, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
March 26, 2024 07:00 ET
|
Cognition Therapeutics, Inc.
- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 -- On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital...
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
March 15, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing product candidates designed to treat...
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
March 14, 2024 16:05 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed...
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
March 11, 2024 20:16 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed...
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
March 11, 2024 16:05 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed...
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
March 06, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the...
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
February 26, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders,...